The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...

The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

By Nqobile Dludla and Siyanda Mthethwa JOHANNESBURG (Reuters) -Danish drugmaker Novo Nordisk introduced its weight-loss drug ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...

At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight-loss jab, through private prescriptions ...

Wegovy is the first GLP-1 treatment approved for MASH. Read more at straitstimes.com. Read more at straitstimes.com.